Document is current
Any future updates will be listed below
-
Authors
Tian, Meijie http://orcid.org/0000-0003-0547-9447
Wei, Jun S. http://orcid.org/0000-0002-4812-0250
Cheuk, Adam Tai-Chi
Milewski, David http://orcid.org/0000-0002-9778-8548
Zhang, Zhongmei
Kim, Yong Yean http://orcid.org/0000-0002-5417-9232
Chou, Hsien-Chao http://orcid.org/0000-0002-4870-9663
Liu, Can http://orcid.org/0000-0002-8411-3891
Badr, Sherif
Pope, Eleanor G. http://orcid.org/0000-0002-4690-7893
Rahmy, Abdelrahman
Wu, Jerry T.
Kelly, Michael C. http://orcid.org/0000-0003-0654-2778
Wen, Xinyu
Khan, Javed http://orcid.org/0000-0002-5858-0488
- License Information
-
More Information
Article History
Received: 24 October 2023
Accepted: 2 July 2024
First Online: 23 July 2024
Competing interests
: J. K. and A.T.C. are inventors on international patent application no. PCT/US2016/052496. The 3A11 CAR sequence is in this patent application (see ) filed on September 19, 2016, titled “Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use”. J.K. and M.T. are inventors on international patent provisional application no. 63/634,330, titled “Chimeric Antigen Receptors Targeting FGFR4 and/or CD276 and Use Thereof for the Treatment of Cancer”. The remaining authors have declared that no conflict of interest exists.
